By CHAD BRAYJULY 28, 2015
LONDON — Hikma Pharmaceuticals of Jordan said on Tuesday that it had agreed to acquire the German drug maker Boehringer Ingelheim’s generic drugs business in the United States for about $2.65 billion in cash and stock.The acquisition of the generics units Roxane Laboratories and Boehringer Ingelheim Roxane is expected to “significantly expand” Hikma’s manufacturing capacity and its technological abilities, the company said.It is the latest in a series of mergers by pharmaceutical companies as they seek new products and try to gain greater scale, and it comes a day after Teva Pharmaceuticals of Israel agreed to buy Allergan’s generic drug business for $40.5 billion.In the latest deal, Hikma would pay $1.18 billion in cash and issue 40 million new shares that would go to Boehringer, representing about 16.71 percent of its outstanding stock.AdvertisementHikma also agreed to make contingency payments of up to $125 million for reaching certain performance targets.Advertisement“This transaction has significant strategic value for us, transforming our position and scale in the U.S. generics market,” Said Darwazah, the chief executive of Hikma, said in a news release. “Roxane’s impressive portfolio, attractive pipeline and R&D expertise, focusing on higher-value, niche and differentiated products, will create a platform for sustainable long-term growth.”Shares of Hikma rose 7.4 percent to 22.34 pounds, or about $34.70, in morning trading in London on Tuesday.Roxane Laboratories, founded in 1885 as the Columbus Pharmaceutical Company, sells more than 80 medications, including oral liquids, tablets, capsules and nasal sprays.Please verify you're not a robot by clicking the box.Invalid email address. Please re-enter.You must select a newsletter to subscribe to.View all New York Times newsletters.It was acquired by Boehringer in 1978. The company employs about 1,360 people and posted a pretax profit of $24 million in 2014.The Roxane transaction is subject to regulatory and shareholder approval and is expected to close in the fourth quarter. Darhold Ltd., Hikma’s largest shareholder, has agreed to vote in favor of the deal, Hikma said.It is not the first acquisition by Hikma of a Boehringer asset. In July 2014, Hikma agreed to acquire Bedford Laboratories, Boehringer’s generic injectable drugs business in the United States, for up to $300 million.Hikma said that in 2017, after the Roxane acquisition, it expected to post revenue of $725 million to $775 million.In 2014, Hikma’s generics business for non-injectable products in the United States generated revenue of $216 million and accounted for about 15 percent of the company’s total revenue.Hikma plans to finance the transaction through a combination of cash and debt.Based in Amman, Jordan, Hikma develops, manufactures and markets branded and nonbranded generic and licensed products in Europe, the Middle East and North Africa and the United States. It posted revenue of $1.49 billion in 2014.AdvertisementCenterview Partners and Citigroup and the law firms White & Case and Slaughter and May advised Hikma, while Morgan Stanley and the law firm Kirkland & Ellis advised Boehringer Ingelheim.A version of this article appears in print on July 29, 2015, on Page B7 of the New York edition with the headline: Drug Merger.  Order Reprints| Today's Paper|Subscribe

We’re interested in your feedback on this page. Tell us what you think.